Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

Aveo’s tivozanib is knocked back by FDA once again

Aveo’s tivozanib is knocked back by FDA once again the TIVO-1 trial of VEGF inhibitor tivozanib – then partnered with Astellas – which compared the drug to Bayer’s VEGF drug Nexavar (sorafenib) in renal cell carcinoma (RCC).

New faces at Healthware Group and HRW

New faces at Healthware Group and HRW Commenting on her new role, Milburn said “from CVS and Sleepio to OneDrop and Bayer, to Happify and Sanofi, every day more and more strategic partnerships are being born between various

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Roche eyes filings for Tecentriq/Avastin combo in liver cancer plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC.

Finalists

by AbbVie. with support from Lucid Group. Marketing Capability Development. by Bayer Russia.

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD Novartis’ drug was the first VEGF inhibitor to reach the market for wet AMD but is facing the triple challenge of Bayer/Regeneron’s rival drug  Eylea (aflibercept) – now the market ... and Bayer adding another $2.1bn from other markets.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics